Jul 9, 2026 · 6 min
European stocks split as drug, pharma and defense names diverge
Astrazeneca's Trial, Schott Pharma Up, Rheinmetall Sinks
The episode shows how clinical setbacks, revised company guidance and sector-wide pressure can send European shares in sharply different directions.
- 1AstraZeneca fell after disappointing clinical trial results for its gene-silencing drug, Wainua.
- 2Redcare Pharmacy surged after raising full-year guidance and receiving an analyst upgrade.
- 3Rheinmetall declined as defense stocks weakened broadly and the company faced a downgrade.
Don't miss
Redcare Pharmacy’s record surge after higher full-year guidance and an analyst upgrade provides the clearest upside contrast in the roundup.
The brief
European stocks are moving on sharply different signals: AstraZeneca absorbs disappointing Wainua trial results, while Redcare Pharmacy benefits from stronger expectations.
Chloe Melley breaks down why AstraZeneca’s gene-silencing drug setback weighed on the company, turning clinical news into an immediate market story.
Redcare Pharmacy delivered the episode’s upside surprise, surging after raising its full-year guidance and receiving an analyst upgrade.
Rheinmetall’s decline reflects a more complicated pressure point: broader weakness across defense stocks compounded by a company-specific downgrade.
Together, the three moves show how European equities can respond differently to clinical evidence, revised guidance and changing sector sentiment.
What was said on this episode
3 statements · 1 positive · 2 negative
Whenua failed to reduce cardiovascular events or deaths in patients with rare heart disease.
“Whenua did not manage to do that, did not manage to reduce cardiovascular events or deaths in those patients.”
Listen at 1:46
Schott Pharma's future growth path appears clear.
“now it seems like that growth Runway is very clear for the company”
Listen at 3:24
Negative sentiment toward the defense industry is weighing on Rheinmetall.
“Rheinmetall this morning is suffering from some of that negative sentiment around this industry”
Listen at 3:54
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
EuropeListen to the full episode and explore every guest, topic, and moment on PodLume.